Molecular monitoring versus standard clinical care in younger adults with AML

Potter N, Jovanovic J, Ivey A, et al; UK AML Research Network

In this study, the authors sought to identify whether altering treatment based on MRD results can improve survival in the UK NCRI AML17 and AML19 Phase 3 trials. Sequential molecular MRD monitoring, coupled with MRD-guided treatment, did not improve overall survival in the entire study population; however, there was a survival benefit for MRD monitoring among patients with baseline NPM1 and FLT3-ITD mutations.